Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Biocon Limited, commonly referred to as Biocon, is a leading Indian pharmaceutical preparation manufacturer headquartered in Bangalore, India. Established in 1978, the company has grown to become a prominent player in the global biopharmaceutical industry, with a strong presence across Asia, North America, and Europe.
Specialising in the development and manufacturing of biosimilars, generic pharmaceuticals, and novel biologics, Biocon is recognised for its innovative approach to healthcare solutions. Its core products include insulin, monoclonal antibodies, and other biopharmaceuticals that address a range of therapeutic areas such as diabetes, oncology, and autoimmune diseases.
Biocon’s commitment to quality and affordability has earned it a notable market position, making it one of India’s most respected biopharmaceutical companies. Its focus on research and development continues to drive its reputation as a pioneer in the pharmaceutical preparation manufacturing industry.
+18 vs industry average
Biocon’s score of 58 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Biocon, a pharmaceutical preparation manufacturer headquartered in India, reported a total of approximately 266.2 billion kg CO2e for the year 2024. This includes Scope 1 emissions of about 38.4 million kg CO2e, Scope 2 emissions of approximately 117.0 million kg CO2e, and Scope 3 emissions totalling about 126.1 million kg CO2e.
In 2023, Biocon's Scope 1 emissions were approximately 45.7 million kg CO2e, and its Scope 2 emissions amounted to roughly 138.5 million kg CO2e. The company also reported Scope 3 emissions for 2022, with business travel accounting for about 1.2 million kg CO2e, employee commute at approximately 7.0 million kg CO2e, purchased goods and services at around 54.7 million kg CO2e, and waste generated in operations at about 6.3 million kg CO2e.
Biocon is committed to reducing its environmental impact. The company has set a near-term target to decrease its Scope 1 and Scope 2 emissions by 25% by the end of FY29, using FY20 data as the baseline. Biocon is reportedly on track to achieve this near-term goal. In addition, Syngene, a part of Biocon, has a long-term target of a 50% reduction in GHG emissions by FY33.
Access structured emission data, company specific factors and auditable source documents
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more